Oxymorphone: all 21 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- Clinical Study to Evaluate the Effectiveness, Safety, and Tolerability of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric SubjectsTerminatedNCT02687451Phase 3Results posted
- Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) ProphylaxisCompletedNCT02625181Not applicableResults posted
- Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric SubjectsCompletedNCT01210352Phase 3Results posted
- Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin)CompletedNCT00955110Phase 4Results posted
- Effect of Extended-release Oxymorphone Taken With or Without Food on Cognitive FunctioningCompletedNCT00930943Phase 4Results posted
- Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.CompletedNCT00801398Phase 3Results posted
- Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric SubjectsTerminatedNCT00765856Phase 3Results posted
- A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)CompletedNCT00580294Not applicableResults posted
- Safety, Tolerability, Effectiveness, and Pharmacokinetic Data in Opioid-experienced ChildrenSuspendedNCT04681027Phase 3
- Bioequivalency Study of Oxymorphone Hydrochloride 10 mg Tablets Under Fasted ConditionsCompletedNCT01210638Phase 1
- Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric SubjectsWithdrawnNCT01206907Phase 3
- A Pilot Study of Ultra Rapid Opioid Rotation and Titration of OxymorphoneStatus unknownNCT00945919Not applicable
- Oxymorphone Extended Release (ER) in Opioid-Naive Patients With Chronic PainCompletedNCT00911287Phase 3
- Oxymorphone Extended Release in Patients With Cancer or Neuropathic PainCompletedNCT00911261Phase 3
- Open Label Assessment of Long-Term Safety and UtilityCompletedNCT00904449Phase 3
- Open-Label Extension to Evaluate the Long-Term Safety, Tolerability and Analgesic EfficacyCompletedNCT00904280Phase 3
- Post-operative Efficacy and Safety StudyCompletedNCT00904085Phase 3
- Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fasted ConditionsCompletedNCT00857428Phase 1
- Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fed ConditionsCompletedNCT00857142Phase 1
- Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant PainCompletedNCT00226421Phase 3
- Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant PainCompletedNCT00225797Phase 3